Kerendia was evaluated in >13,000 patients with early-to late-stage CKD*

99.8% of patients were on the maximum tolerated dose of an ACEi or ARB, and 97.7% were on at least one glucose-lowering agent

FIGARO-DKD TRIAL (CV-FOCUSED)	FIDELIO-DKD TRIAL (RENAL-FOCUSED)
Primary composite endpoint: CV death Non-fatal MI Non-fatal stroke HF hospitalisation	Primary composite endpoint: Kidney failure Sustained decline of ≥40% in eGFR Kidney death

Kerendia was evaluated in a large phase 3 clinical trial program

	FIGARO-DKD	FIGARO-DKD	FIDELIO-DKD	FIDELIO-DKD
Baseline Characteristics	Kerendia (n=3686)	Placebo (n=3666)	Kerendia (n=2833)	Placebo (n=2841)
Mean eGFR (mL/min/1.73 m²)	67.6	68.0	44.4	44.3
eGFR <45 mL/min/1.73 m² (% of patients)	17.8	16.9	54.4	55.4
History of CVD (% of patients)
Coronary artery diseas	31.1	31.3	29.7	30.3
MI	17.4	16.8	13.3	13.7
Peripheral arterial occlusive disease	15.9	15.7	16.6	15.9
Ischemic stroke	12	11.6	11.6	12.7
Heart failure (% of patients)	7.9	7.7	6.9	8.5
Urinary albumin-to-creatinine ratio
Median (IQR)	302 mg/g	315 mg/g	833 mg/g	867 mg/g
Glycated haemoglobin (%)	7.7±1.4	7.7±1.4	7.7±1.3	7.7±1.4
Systolic blood pressure (mmHg)	135.8±14.0	135.7±14.1	138.1±14.3	138.0±14.4
Select baseline medications (% of patients)
ACEi^§	42.8	42.6	33.5	34.9
ARB^§	57.2	57.4	66.3	65.0
Glucose-lowering therapies	97.9	97.9	97.0	97.7
Insulin	54.9	53.7	64.1	63.1
Metformin	69.5	68.4	44.2	43.6
GLP-1 receptor agonists	8.4	6.6	6.7	7.2
SGLT2 inhibitors	8.5	8.3	4.4	4.8
Statins	69.2	71.8	74.3	74.3
Antiplatelet agents	55.5	53.3	57.6	56.1